PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29595642
OWN - NLM
STAT- MEDLINE
DCOM- 20180405
LR  - 20180405
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 13
DP  - 2018 Mar
TI  - Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic
      kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant
      article.
PG  - e0161
LID - 10.1097/MD.0000000000010161 [doi]
AB  - BACKGROUND: To investigate the efficacy of febuxostat in hyperuricemic patients
      with chronic kidney disease (CKD), relevant randomized clinical trials (RCTs)
      were analyzed. METHODS: We used PubMed, Medline, ISI Web of Science, CBMdisc, and
      Cochrane Library databases to conduct a systematic literature research. A
      fixed-effects model was used to evaluate the standardized mean differences (SMDs)
      with 95% confidence intervals (CIs). We conducted subgroup analysis, sensitivity 
      analysis, and analyzed publication bias, to comprehensively estimate the
      renoprotective effects of febuxostat in hyperuricemic patients with CKD. RESULTS:
      Among 296 retrieved studies, 5 relevant RCTs were included in the meta-analysis. 
      The result showed that serum estimated glomerular filtration rate (eGFR) was
      improved after febuxostat treatment in hyperuricemic patients with CKD, with an
      SMD (95% CI) of 0.24 [-0.17 to 0.43] and P = .67 (fixed-effects model). No
      heterogeneity was observed across studies (I = 0% and P = .67). Subgroup analysis
      suggested that treatment-related reductions in serum eGFR levels were not related
      to drug doses, intervention times, or region. CONCLUSIONS: The present
      meta-analysis suggests that febuxostat may slow the progression of
      mild-to-moderate CKD. Given the limited number of included studies, additional
      large sample-size RCTs are required to determine the long-term renoprotective
      effects of febuxostat in hyperuricemic patients with CKD.
FAU - Zeng, Xiang Xia
AU  - Zeng XX
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang
      University.
FAU - Tang, Yunliang
AU  - Tang Y
AD  - Department of Endocrinology and Metabolism, The Third Hospital of Nanchang,
      Nanchang, Jiangxi, China.
FAU - Hu, Kaixiang
AU  - Hu K
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang
      University.
FAU - Zhou, Xi
AU  - Zhou X
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang
      University.
FAU - Wang, Jiao
AU  - Wang J
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang
      University.
FAU - Zhu, Lingyan
AU  - Zhu L
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang
      University.
FAU - Liu, Jianying
AU  - Liu J
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang
      University.
FAU - Xu, Jixiong
AU  - Xu J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Gout Suppressants)
RN  - 101V0R1N2E (Febuxostat)
SB  - AIM
SB  - IM
MH  - Febuxostat/*therapeutic use
MH  - Gout Suppressants/*therapeutic use
MH  - Humans
MH  - Hyperuricemia/*complications/*drug therapy
MH  - Renal Insufficiency, Chronic/*complications
EDAT- 2018/03/30 06:00
MHDA- 2018/04/06 06:00
CRDT- 2018/03/30 06:00
PHST- 2018/03/30 06:00 [entrez]
PHST- 2018/03/30 06:00 [pubmed]
PHST- 2018/04/06 06:00 [medline]
AID - 10.1097/MD.0000000000010161 [doi]
AID - 00005792-201803300-00015 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Mar;97(13):e0161. doi: 10.1097/MD.0000000000010161.